Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SLC13A5 | Q86YT5 | 6/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416152 | 0.86 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAMAPTTSHR | |
| SCHEMBL37069 | 0.82 | ALDH1A1 (0.58) | ALDH1A1KDM4ELMNAMAPTTSHR | |
| Water SCHEMBL17966763 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAMAPTTSHR | |
| Ammonia Solution, Strong SCHEMBL21219077 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAMAPTTSHR | |
| SCHEMBL1648052 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAMAPTTSHR | |
| SCHEMBL27805119 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4ELMNAMAPTTSHR | |
| Citric Acid SCHEMBL21145087 | 0.80 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAMAPTTSHR | |
| Citric Acid SCHEMBL6654790 | 0.80 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAMAPTTSHR | |
| SCHEMBL25376169 | 0.79 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAMAPTTSHR | |
| SCHEMBL28424349 | 0.79 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CATALENT PHARMA SOLUTIONS, LLC | 2024-05-09 | — | — | US | disclosed |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS, LLC | 2024-03-14 | — | — | US | disclosed |
| WO-2024049734-A1 | IMPLANTABLE DEVICE FOR INTRATUMORALLY ADMINISTERING A THERAPEUTIC AGENT | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240050415-A1 | DACLATASVIR FOR USE IN TREATING LUNG AND PROSTATE CANCER | HENRY FORD HEALTH SYSTEM (US) | 2024-02-15 | — | — | US | disclosed |
| US-11879009-B2 | Multifunctional protein molecules comprising decorin and use thereof | CATALENT PHARMA SOLUTIONS, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2023172387-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF AROMATASE INHIBITOR | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023163914-A1 | INTRAVAGINAL RING DEVICE FOR THE DELIVERY OF AROMATASE INHIBITOR | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023049095-A1 | REFILLABLE IMPLANTABLE DEVICE FOR DELIVERING A DRUG COMPOUND | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20090082295-A1 | COMBINATIONS AND METHODS OF USING AN IMMUNOMODULATORY OLIGODEOXYNUCLEOTIDE | PFIZER INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090010878-A1 | Pulsatile dosing of gossypol for treatment of disease | ASCENTA THERAPEUTICS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080253997-A1 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS FROM TOXIC EXPOSURES | PERSCITUS BIOSCIENCES, LLC (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1938105-A1 | METHOD TO ASSESS BREAST CANCER RISK | The Children's Medical Center Corporation (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080095755-A1 | Methods and compositions for the treatment of cancer | QUINTESSENCE BIOSCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080021110-A1 | Production of gossypol co-crystals | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021095-A1 | Small Molecule Antagonists of Xiap Family Proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2008-01-24 | — | — | US | disclosed |
| US-20080019961-A1 | Hedgehog signaling pathway antagonist cancer treatment | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2007059313-A1 | METHOD TO ASSESS BREAST CANCER RISK | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20050261232-A1 | Non-natural ribonuclease conjugates as cytotoxic agents | QUINTESSENCE BIOSCIENCES, INC. (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CD2BP2, DSTN, SDCBP | ALDH1A1 3337/4885KDM4E 4354/4885LMNA 2473/4885 |
| US-11879009-B2 | Multifunctional protein molecules comprising decorin and use thereof | CD2BP2, DSTN, SDCBP | ALDH1A1 3337/4885KDM4E 4354/4885LMNA 2473/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | ALDH1A1 4447/4885KDM4E 2643/4885LMNA 3609/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | ALDH1A1 4447/4885KDM4E 2643/4885LMNA 3609/4885 |
| US-20090010878-A1 | Pulsatile dosing of gossypol for treatment of disease | BCL2, BAX, PHLPP2 | ALDH1A1 4787/4885KDM4E 2940/4885LMNA 1515/4885 |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | ALDH1A1 4447/4885KDM4E 2643/4885LMNA 3609/4885 |
| US-20080021095-A1 | Small Molecule Antagonists of Xiap Family Proteins | XIAP, BIRC5, BIRC3 | ALDH1A1 2921/4885KDM4E 3013/4885LMNA 421/4885 |
| US-20080253997-A1 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS FROM TOXIC EXPOSURES | PRDX5, GPX1, GPX4 | ALDH1A1 267/4885KDM4E 4065/4885LMNA 261/4885 |
| US-20090082295-A1 | COMBINATIONS AND METHODS OF USING AN IMMUNOMODULATORY OLIGODEOXYNUCLEOTIDE | DCLRE1B, TLR3, CD74 | ALDH1A1 2928/4885KDM4E 2818/4885LMNA 3502/4885 |
| US-20050261232-A1 | Non-natural ribonuclease conjugates as cytotoxic agents | RNASE1, RNASEL, RNASEH1 | ALDH1A1 2489/4885KDM4E 3074/4885LMNA 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.